Musclepharm Corp Performance
| MSLPDelisted Stock | USD 0 0.0002 15.38% |
The company secures a Beta (Market Risk) of 2.38, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Musclepharm Corp will likely underperform. Musclepharm Corp right now secures a risk of 0.0%. Please verify Musclepharm Corp potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Musclepharm Corp will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Musclepharm Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable essential indicators, Musclepharm Corp is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 2 M | |
| Total Cashflows From Investing Activities | -2000.00 |
Musclepharm |
Musclepharm Corp Relative Risk vs. Return Landscape
If you would invest 0.11 in Musclepharm Corp on January 31, 2024 and sell it today you would earn a total of 0.00 from holding Musclepharm Corp or generate 0.0% return on investment over 90 days. Musclepharm Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Musclepharm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Musclepharm Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Musclepharm Corp's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Musclepharm Corp, and traders can use it to determine the average amount a Musclepharm Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MSLP |
Based on monthly moving average Musclepharm Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Musclepharm Corp by adding Musclepharm Corp to a well-diversified portfolio.
Musclepharm Corp Fundamentals Growth
Musclepharm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Musclepharm Corp, and Musclepharm Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Musclepharm Pink Sheet performance.
| Return On Asset | -0.66 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.23) % | |||
| Current Valuation | 22.12 M | |||
| Shares Outstanding | 34.35 M | |||
| Price To Sales | 0 X | |||
| Revenue | 50.04 M | |||
| EBITDA | (7.07 M) | |||
| Cash And Equivalents | 534 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 22.64 M | |||
| Debt To Equity | 0.56 % | |||
| Book Value Per Share | (1.14) X | |||
| Cash Flow From Operations | (8.04 M) | |||
| Earnings Per Share | (0.58) X | |||
| Total Asset | 11.21 M | |||
| Retained Earnings | (159.76 M) | |||
| Current Asset | 32.9 M | |||
| Current Liabilities | 53.88 M | |||
About Musclepharm Corp Performance
To evaluate Musclepharm Corp Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Musclepharm Corp generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Musclepharm Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Musclepharm Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Musclepharm's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company was incorporated in 2006 and is based in Las Vegas, Nevada. MUSCLE PHARM operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 21 people.Things to note about Musclepharm Corp performance evaluation
Checking the ongoing alerts about Musclepharm Corp for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Musclepharm Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Musclepharm Corp is not yet fully synchronised with the market data | |
| Musclepharm Corp has some characteristics of a very speculative penny stock | |
| Musclepharm Corp has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 22.64 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. Musclepharm Corp has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Musclepharm Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Musclepharm Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Musclepharm Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Musclepharm to invest in growth at high rates of return. When we think about Musclepharm Corp's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 50.04 M. Net Loss for the year was (12.87 M) with profit before overhead, payroll, taxes, and interest of 5.37 M. | |
| Musclepharm Corp currently holds about 534 K in cash with (8.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 54.0% of Musclepharm Corp outstanding shares are owned by corporate insiders |
- Analyzing Musclepharm Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Musclepharm Corp's stock is overvalued or undervalued compared to its peers.
- Examining Musclepharm Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Musclepharm Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Musclepharm Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Musclepharm Corp's pink sheet. These opinions can provide insight into Musclepharm Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Musclepharm Pink Sheet
If you are still planning to invest in Musclepharm Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Musclepharm Corp's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |